Learn how personalized cancer therapy can help you.
We believe cancer therapy should be personal—and that’s why we harness the power of your tumor to enable that. Our unique platform assesses the tumor sample your doctor submits using a set of genomic and functional tests that determine both your tumor’s mutations and how your tumor responds to drugs. This information can help your oncologist individualize your therapy to your unique characteristics. Scroll to learn more.
Helomics is now part of Predictive Oncology.
Commonly asked questions
Drug-response profiling is a treatment selection marker. It determines how an individual cancer patient’s tumor is likely to respond to the various types of chemotherapy by testing the treatment options on that patient’s live cancer cells and measuring cell response. This provides valuable insights that help guide physicians’ treatment decisions, giving you an edge against cancer.
Genomic testing is a group of clinically relevant cancer-related biomarker tests that look at your genetics to predict your cancer’s response to various types of chemotherapy and/or the course your disease is likely to take. The biomarkers included in genomic testing are well-validated and supported by current research and key opinion leaders.
Your physician is using every advantage available to improve the odds in your fight against cancer. Combining drug-response profiling and genomic profiling of your tumor generates a more comprehensive picture to provide information to help your oncologist individualize your therapy. These tests are designed to reduce your risk of receiving therapies that are ineffective or to identify alternatives when the typical treatments recommended for your type of cancer cannot be tolerated.
Tumor tissue is obtained during surgery and your oncologist will send that tissue to our CLIA-certified laboratory using our special collection kit. Two samples of your tumor tissue are obtained, fixed and live. The fixed tumor tissue is used for a panel of genomic biomarker tests. The live tumor tissue is grown in the lab and used to test the drug response of the tumor to a panel of standard-of-care (SOC) drugs. When testing is complete a report is provided back to your clinician with recommended SOC therapies based on the drug response and genomic profiles.
The data generated from testing the unique mutations of your tumor and from the drug response profiling, which essentially performs chemotherapy on your tumor outside of the body, provides information to your oncologist to improve the odds in your fight against cancer. In addition, and with your consent, de-identified data generated by testing your tumor is added to our cancer knowledgebase of existing tumor data. Deeper analysis of this data will improve the recommendations we give to clinicians to help patients like you, as well as provide insights to guide research into new cancer therapies.
We are committed to providing access to functional precision medicine to as many people as possible. Our panel of biomarker/genomic tests are covered by most insurers/Medicare. We have continued to offer tumor drug-response tests amidst reimbursement uncertainty from both commercial insurers and Medicare. Due to continued clinical demand, we remain committed to meeting the needs of patients. To keep this testing available to patients and their treating physicians, we offer our tumor drug-response profiling at a drastically reduced rate such that no patient will pay more than $615. We also provide a Compassionate Care Program for those patients who need further help with payment. Contact us for more information.
Get in touch to learn more.
Complete the form with questions about future or previous tests.